Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for neurological diseases. Its pipelines includes LP352, LP143 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others. LP143 is a centrally acting, full cannabinoid type 2 receptor (CB2) agonist in investigational new drug application (IND)-enabling studies for neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS). LP659 is a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)